Pretreated EGFR(del19)/BRAF(V600E) Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report

Oncogene-addicted NSCLC inevitably becomes resistant to targeted therapy by developing acquired resistance through on- or off-target mechanisms, potentially detectable by liquid biopsy. We present the first reported case of a patient with pretreated EGFR(del19)/BRAF(V600E) lung adenocarcinoma and sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Orciuolo, Corrado, Cappuzzo, Federico, Landi, Lorenza, Resuli, Blerina, Carpano, Silvia, Vidiri, Antonello, Buglioni, Simonetta, Mandoj, Chiara, Ciliberto, Gennaro, Minuti, Gabriele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392131/
https://www.ncbi.nlm.nih.gov/pubmed/37533438
http://dx.doi.org/10.1016/j.jtocrr.2023.100545
Descripción
Sumario:Oncogene-addicted NSCLC inevitably becomes resistant to targeted therapy by developing acquired resistance through on- or off-target mechanisms, potentially detectable by liquid biopsy. We present the first reported case of a patient with pretreated EGFR(del19)/BRAF(V600E) lung adenocarcinoma and symptomatic leptomeningeal metastasis obtaining durable clinical benefit on osimertinib, dabrafenib, and trametinib treatment.

Ejemplares similares